+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Age: 18Years - 89Years
All Genders
ID06140134

Phase II Study of Liver Transplantation After Neoadjuvant Therapy for Locally Advanced Unresectable Intrahepatic Cholangiocarcinoma

Led by Rutgers, The State University of New Jersey · Updated on 2026-03-20

30

Participants Needed

2

Research Sites

52 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating liver transplantation as a treatment option for patients with biologically responsive locally advanced non-metastatic intrahepatic cholangiocarcinoma iCCA who have undergone neoadjuvant systemic therapy. This study aims to compare overall survival rates of these patients after liver transplantation to historical outcomes of patients treated only with chemotherapy. Intrahepatic cholangiocarcinoma is a primary liver cancer with poor survival rates following surgical resection due to high tumor recurrence. The study involves patients with locally advanced unresectable iCCA who have shown at least 6 months of disease stability or regression on neoadjuvant systemic therapy. Eligible patients are listed for liver transplantation and receive a whole liver allotransplant when a matching donor liver becomes available. This single-center phase II study tracks patients listed for transplant and compares outcomes between those who receive the transplant and those who expire or are removed from the waiting list. Participants will be closely monitored before and after transplantation, with assessment of overall survival over 5 years as the primary outcome. Secondary outcomes include recurrence-free survival, intent-to-treat overall survival, and post-transplant functional assessments to identify complications and morbidities. Follow-up includes evaluations for tumor progression, monitoring of adverse events, and compliance with study procedures, with total participation lasting up to 5 years.

CONDITIONS

Brief Title

Liver Transplantation in Intrahepatic Cholangiocarcinoma

Research Team

M

Melissa Lugardo

A

Angenie Preval, PA

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here